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microbiome, and the environment, play an im‑
portant role in disturbing intestinal homeosta‑
sis, leading to a dysregulated inflammatory re‑
sponse in the gastrointestinal tract.1,3,4 Oxida‑
tive stress, an imbalance between the release of 
reactive oxygen species (ROS) and reactive nitro‑
gen species and neutralization activity, is an im‑
portant pathogenetic factor in CD.3,5,6 Hydrogen 
peroxide levels in immune cells of CD patients 
are correlated with indicators of inflammation 
(eg, tumor necrosis factor α [TNF ‑α], interleu‑
kin 1 [IL ‑1], IL ‑6, and IL ‑8).7-11 ROS are generated 
by resident phagocytic cells, microvascular endo‑
thelial cells, and mucosal epithelial cells.12-15 More‑
over, activated cyclooxygenase and lipoxygenase 
generate ROS and are responsible for producing 
IntroductIon Crohn disease (CD) is a chron‑
ic illness of the entire gastrointestinal tract and 
is characterized by recurrent granulomatous in‑
flammation of unknown etiology.1 The active dis‑
ease manifests with symptoms such as abdominal 
pain, weight loss, chronic diarrhea, and fever and 
with severe complications such as malnutrition, 
intestinal strictures, fistulas, and intra ‑abdominal 
abscess.1 Laboratory parameters evaluated in CD 
patients include C ‑reactive protein (CRP), a bio‑
chemical marker of disease activity; however, CRP 
is more useful for assessing or monitoring disease 
activity than for diagnosis.2
The precise etiopathogenesis of CD is unclear. 
Interactions among various factors, including 
genetics, the  immune system, the  intestinal 
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IntroductIon Increased oxidative stress has been implicated in the pathogenesis of Crohn disease 
(CD). Except for C ‑reactive protein (CRP), good biological markers of CD activity are lacking.
objEctIvEs We aimed to investigate the diagnostic usefulness of selected markers of oxidative stress 
in the serum and saliva of patients with active and inactive CD.
PAtIEnts And MEthods A total of 58 patients with confirmed CD (32 with active CD, 26 with inactive CD, 
and 26 healthy controls) were prospectively enrolled to the study. The markers examined were malondi‑
aldehyde (MDA), ferric reducing ability of plasma (FRAP), reduced glutathione (GSH), and catalase (CAT).
rEsuLts MDA levels were higher in the serum and saliva of patients with active CD than in those with 
inactive CD and controls and were positively correlated with the Crohn’s Disease Activity Index (r = 
0.8, P <0.001) and CRP (P <0.001). Serum and saliva antioxidant indicators (FRAP and GSH) were 
decreased in both CD groups compared with controls and were negatively correlated with clinical activity 
and inflammation (FRAP, r = –0.5, P <0.001; GSH, r = –0.5, P <0.001; and CAT, r = –0.5, P <0.001).
concLusIons The increased lipid peroxidation and decreased antioxidant activity in serum and saliva 
confirm that CD patients are under oxidative stress. The positive correlations of MDA with the clinical 
activity and inflammation, as well as the comparison of the receiver operating characteristic curves for 
MDA and CRP, suggest that MDA could be a good diagnostic marker of CD.
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smoking; the use of antibiotics, antioxidants 
or anti ‑inflammatory medications in the past 
6 months; pregnancy or lactation; periodontal 
disease; the presence of oral mucosal disease; and 
the use of orthodontic appliances. Exclusion cri‑
teria for CD patients were also the current treat‑
ment with biologic therapy, the presence of ab‑
dominal abscess, intestinal stricture, and active 
gastrointestinal bleeding.37
The  Bioethics Committee of Jagiellonian 
University approved the study protocol (No. 
KBET/200/B/2014). The study was performed 
in accordance with the  ethical principles of 
the 2008 Declaration of Helsinki. All subjects 
provided written informed consent before par‑
ticipating in the study.
sample collection and storage Fasting blood sam‑
ples were collected in tubes containing K2 ‑EDTA 
or free of anticoagulant. Blood was centrifuged 
at 3000 × g for 10 minutes at 4°C and serum was 
carefully separated. Serum samples were stored 
at –80°C for 6 months before the assessment of 
MDA, FRAP, and GSH concentrations as well as 
catalase (CAT) activity. The routine laboratory 
tests including complete blood count, platelet 
count, hemoglobin, and serum CRP levels were 
performed in the hospital laboratory using stan‑
dard procedures.
Unstimulated whole saliva samples were col‑
lected in 10 ‑ml sterilized and precooled polypro‑
pylene tubes from fasted participants between 
8:00 AM and 10:00 AM. All subjects were asked 
to avoid oral hygiene measures, eating, drinking, 
or gum chewing for a minimum of 2 hours prior 
to sampling. The individuals rinsed their mouths 
with tap water and expectorated prior to the col‑
lection of saliva. The saliva samples were placed 
on ice and transported to the laboratory. Saliva 
was centrifuged at 1000 × g for 10 minutes at 4°C, 
and the supernatant was immediately aliquoted 
to sterile 1.5 ‑ml test tubes and frozen at –80°C.
Laboratory analysis MDA levels were deter‑
mined using the colorimetric method of Buege 
and Aust20 based on thiobarbituric acid (TBA) 
reactivity, as described previously.31 MDA was 
quantified by reaction with TBA and measure‑
ment of the pink chromophore produced. Ali‑
quots (0.5 ml) of samples were mixed with 1 ml 
of reagent mixture prepared by diluting stock 
solution, containing 30 g of trichloroacetic acid 
(TCA; 15% final), 4.16 ml of concentrated HCl 
(0.2 N final), 0.74 g of TBA; 0.37% final), and 
H2O, to 0.2  l. The stock solution (TCA/HCl/
TBA) was heated to 70°C and dissolved in wa‑
ter 4 times to yield a working solution. Butylated 
hydroxytoluene in ethanol was added to a final 
concentration of 0.03%. After shaking, the tube 
was placed into a boiling water bath for 15 min‑
utes. After cooling, the resulting chromogen was 
extracted with 3 ml of butyl alcohol by vigor‑
ous shaking for 1 minute. Separation of the or‑
ganic phase was facilitated by centrifugation 
several proinflammatory cytokines (eg, TNF ‑α, 
IL ‑1, and IL ‑8) and other active molecules lead‑
ing to cell damage.7,16,17 Increased production of 
ROS damages double bonds in polyunsaturated 
fatty acids, inducing lipid peroxidation and oxi‑
dative damage.18-20
Lipid peroxidation is involved in the patho‑
genesis of numerous inflammatory diseases and 
malignancies.16,21-23 Lipid peroxidation produc‑
es malondialdehyde (MDA) / thiobarbituric acid‑
‑reactive substances (TBARS), which are used to 
detect changes in oxidant status.10,19,22,24 Antiox‑
idant defenses, such as total antioxidant capacity 
measured using ferric reducing ability of plasma 
(FRAP) and glutathione (GSH), limit cell injury 
induced by ROS.10,22,23 The persistence of oxida‑
tive stress in CD affects the course of the disease 
and is associated with some of its characteristic 
features and complications.3,11,15,21,25-27
The levels of oxidative stress markers can be de‑
termined with invasive techniques such as blood 
sampling; however, the use of human saliva is 
a noninvasive alternative. There is a correlation 
between salivary levels of inflammatory markers 
and the clinical severity of CD.27-29 Saliva contains 
many biomarkers that reflect local and systemic 
diseases and may facilitate their diagnosis, prog‑
nosis, and therapeutic responsiveness.20,22,30 -32 
Therefore, identifying oxidative stress markers 
in the saliva of CD patients may be of great clin‑
ical interest.
Except for CRP, there is a lack of good biolog‑
icals marker of CD activity.33,34 We aimed to in‑
vestigate the diagnostic usefulness of selected 
markers of oxidative stress in the serum and sa‑
liva of patients with active and inactive CD com‑
pared with healthy controls.
PAtIEnts And MEthods study population Fifty‑
‑eight adult patients (27 women, 31 men) diag‑
nosed with CD were prospectively recruited be‑
tween December 2014 and January 2016 from 
the gastroenterology clinic of the University Hos‑
pital in Kraków, Poland. The control group consist‑
ed of 26 healthy volunteers (12 women, 14 men). 
Patients were divided into 2 groups: with active 
CD (n = 32) and with inactive CD (in remission; 
n = 26). The diagnosis of CD was based on clin‑
ical, endoscopic, histopathological, and radio‑
logical criteria.1 The severity of CD was deter‑
mined using the Crohn’s Disease Activity Index 
(CDAI).1,35 A CDAI lower than 150 indicates dis‑
eases remission, and that of 150 or higher—ac‑
tive CD (150–219, mild exacerbation; 220–450, 
moderate; >450, severe exacerbation).1,35 Patients 
were treated with azathioprine (2.0–2.5 mg/kg/d) 
according to the European Crohn’s and Colitis Or‑
ganisation guidelines.36 Patients with inflamma‑
tory lesions in the colon were additionally treat‑
ed with mesalamine (2 g/d).
The characteristics of the study groups are 
shown in tAbLE 1. The exclusion criteria included 
severe systemic disease; diabetes; chronic inflam‑
mation; symptoms of acute illness; alcohol abuse; 
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layer) was used for examination. White blood cells 
were diluted 1:0.5 v/v in culture medium RPMI 
1640 (Gibco) with fetal bovine serum (10%), pen‑
icillin (100 U/ml), and streptomycin (1009 μg/ml) 
and incubated at 37°C. The cells were counted 
and the suspensions were standardized to obtain 
106 white blood cells in 1 ml of RPMI. The cells 
were homogenized and centrifuged at 10 000 × g 
for 20 minutes at 4°C. A supernatant was used 
to test the catalase activity. The procedures were 
carried out on ice.
CAT activity was measured using the Catalase 
Activity Assay Kit (Randox Laboratories Ltd, Lon‑
don, United Kingdom) according to the manufac‑
turer’s instruction. Briefly, CAT present in white 
blood cells reacts with hydrogen peroxide (H2O2) 
to produce water and oxygen. In the presence of 
horseradish peroxidase, unconverted H2O2 re‑
acts 1:1 with the substrate 10 ‑acetyl ‑3,7 ‑dihy
droxyphenoxazine to form resorufin, which is 
measured fluorimetrically at the excitation and 
emission wavelength maximum of 535 nm and 
587 nm, respectively, with a FLUOstar Omega 
spectrophotometer.
statistical analysis Data were expressed as per‑
centages for categorical variables, as mean with 
standard deviation (SD) for normally distrib‑
uted continuous variables, and as median with 
interquartile range for nonnormally distribut‑
ed continuous variables. The Shapiro–Wilk test 
was used to assess the normality of the data dis‑
tribution. Results with a Gaussian distribution 
were analyzed by the t test. The nonparametric 
Mann–Whitney test and the χ2 test were used 
to compare variables between groups. Oxidative 
stress marker levels were not normally distribut‑
ed; therefore, we performed statistical compar‑
isons of groups using the Kruskal–Wallis test, if 
the difference was significant; the post hoc test 
was used to assess significant pairwise differenc‑
es. The associations between multiple variables 
were assessed using the Spearman rank correla‑
tion coefficient. The diagnostic usefulness of ox‑
idant–antioxidant indicators was calculated by 
receiver operating characteristic (ROC) curves. 
The marker overall performance was expressed 
in terms of the area under the ROC curve (AUC) 
with 95% CI and P statistics for the difference be‑
tween the calculated AUC and AUC of 0.5 (index 
with no discriminating power). A cut ‑off value 
corresponding to the highest accuracy was deter‑
mined and the related sensitivities and specifici‑
ties, summarized in the Youden index (sensitivi‑
ty, specificity). We performed statistical analyses 
using Statistica 10.0 (StatSoft, Tulsa, Oklahoma, 
United States) and SPSS version 22.0 for Windows 
(SPSS, Chicago, Illinois, United States). The sig‑
nificance level was set at an α value of 0.05 for 
the 2 ‑tailed test.
rEsuLts The hemoglobin concentration was 
lower in patients with active CD than in inac‑
tive CD and controls (P = 0.01 and P = 0.05, 
at 2000 × g for 10 minutes. The TBA ‑MDA ad‑
duct was quantified using fluorescence emis‑
sion at 553 nm with excitation at 532 nm, and 
the TBA ‑MDA concentration was calculated from 
a standard curve of 0 to 50 nmol MDA/sample 
using 1,1,3,3 ‑tetramethoxypropane as the stan‑
dard. The measurements were performed on 
a FLUOstar Omega spectrophotometer (BMG 
Labtech, Ortenberg, Germany). MDA concen‑
trations were expressed as nmol/mg protein.
Total antioxidant capacity was measured 
using FRAP according to Benzie et al,38 as de‑
scribed previously.31 We obtained FRAP values 
by measuring ferric to ferrous ion reduction 
at low pH (0.3 ‑M acetate buffer; pH, 3.6) cou‑
pled with 2,4,6‑Tris(2‑pyridyl)‑s‑triazine, whose 
absorbance was measured at a wavelength of 
593 nm on a FLUOstar Omega spectrophotom‑
eter. The serum and saliva samples were centri‑
fuged at 1000 × g for 15 minutes (0–4°C). Aliquots 
(0.1 ml) of the supernatants were mixed with 
3 ml of reagent mixture containing 25 ml of ac‑
etate buffer (0.3 M; pH, 3.6), 0.25 ml 2,4,6 ‑tri
s(2 ‑pyridyl)‑s ‑triazine (5 mM TPTZ) in 40 mM 
of HCl, and 0.25 ml of ferric solution (20 mM 
FeCl3) in distilled water. We calculated FRAP val‑
ues by preparing an aqueous solution of known 
FeII concentration in the range of 0 to 1000 μM 
(FeSO4∙7H2O), and the blank contained FRAP 
reagent mixture. Reactions were performed for 
5 minutes at 37°C. FRAP values were expressed 
as mmol/mg of protein.
GSH levels were determined using the Ellman 
method, as described previously.31,39 The method 
is based on the reaction of thiols with the chro‑
mogen DTNB (5,5’‑dithiobis ‑2‑nitrobenzoic acid), 
whereby the formation of the yellow dianion of 
5 ‑thio ‑2‑nitrobenzoic acid is measured.40 Absor‑
bance was read 5 minutes after the supernatant 
was introduced at room temperature at a wave‑
length of 412 nm on a FLUOstar Omega spectro‑
photometer (BMG Labtech). GSH concentrations 
were expressed as nmol/mg of protein.
Total protein levels were determined using 
the bicinchonic acid (BCA) method in accordance 
with the manufacturer’s instructions (Sigma‑
‑Aldrich, city, state, United States), with bovine 
serum albumin as the standard, as described pre‑
viously.41 The BCA method entails reducing Cu2+ to 
Cu+, whereby Cu+ ions react in an alkaline medi‑
um with BCA, which gives it a violet color. Absor‑
bance was determined at a wavelength of 562 nm 
at 37°C on a FLUOstar Omega spectrophotome‑
ter. A calibration curve was plotted, and a simple 
linear regression equation derived. Protein con‑
centrations were expressed in mg/ml.
To determine CAT activity in white blood cells, 
they were isolated from whole blood by centrif‑
ugation in a  Histopaque density gradient of 
1.077 g/ml; 5 ml of blood was gently layered onto 
7 ml of Histopaque 1077 (Sigma ‑Aldrich) in a 15‑
‑ml conical tube and centrifuged at room temper‑
ature for 40 minutes at 230 × g with zero decel‑
eration. Plasma rich in white blood cells (upper 
orIGInAL ArtIcLE Lipid peroxidation and Crohn disease 365
active CD were lower than in inactive CD and con‑
trols (P <0.01) (tAbLE 2). There were no differences 
in saliva FRAP levels between active CD and inac‑
tive CD; however, both FRAP concentrations were 
lower than those of controls. Saliva FRAP levels 
were higher than those in serum in all subjects. 
Serum and saliva GSH levels were lower in active 
CD patients compared with those with inactive 
CD and controls (P <0.01) (tAbLE 2). The distribu‑
tion of CAT activity differed between active CD 
and controls (P = 0.001) and between active CD 
and inactive CD (P = 0.001) (tAbLE 2).
The correlations between CD activity (assessed 
by CDAI), lipid peroxidation levels, and antioxi‑
dant parameters in serum and saliva are shown 
in tAbLE 3. The correlations of MDA levels in serum 
respectively). The platelet count and serum CRP 
levels were higher in patients with active CD 
than in those with inactive CD and controls 
(both P <0.05). The mean CDAI score of patients 
with active CD was also higher than in those 
with inactive disease (P = 0.01). The ileocecal re‑
gion was the most frequent localization of CD 
lesions. Detailed data are presented in tAbLE 1. 
Fourteen patients had mild CD activity (CDAI, 
150–219 points), and 10 had moderate CD ac‑
tivity (CDAI, 220–450 points).
Serum and saliva MDA levels were elevated in 
active CD compared with inactive CD and controls 
(P <0.01) (tAbLE 2). MDA levels in saliva were high‑
er than those in serum in active CD, inactive CD, 
and controls. Serum FRAP levels of patients with 
tAbLE 1 Characteristics of patients with active and inactive Crohn disease and controls
Parameter Active CD
(n = 32)
Inactive CD
(n = 26)
Control
(n = 26)
Age, y, n (%) 34.6 (11.3) 36.1 (15.1) 33.8 (9.6)
Sex, male/female, n 19/13 17/9 14/12
Disease duration, y 8.3 (3.9) 9.9 (4.2) NA
BMI, kg/m2 22.4 (2.7) 24.6 (3.1) 23.8 (2.7)
Hemoglobin, g/l 112 (1.6)a,b 134 (1.3) 139 (1.6)
Red blood cell, × 1012/l 3.8 (0.3) 4.2 (0.4) 4.8 (0.3)
White blood cell, × 109/l 8.7 (3.2) 6.8 (3.9) 5.2 (1.1)
Platelet count, × 103/μl, median (IQR) 397.4 (239.0–463.1)b,c 265.1 (240–286.3) 249.5 (223.4–296.8)
CRP, mg/l, median (IQR) 38.3 (18.5–49.2)d 1.8 (0.7–3.4) 1.6 (0.5–3.9)
CDAI, points 270.8 (31.2)a 67.2 (21.4) NA
Localization of 
lesions, %
Small intestine 24% 18.2% NA
Large intestine 12% 18.2%
Ileocecal disease 64% 59.1%
Perianal disease 6% 8.2%
Data presented as mean (SD) unless otherwise indicated.
a P = 0.01 compared with inactive CD;   b P = 0.05 compared with control;   c P = 0.05 compared 
with inactive CD;   d P = 0.001 compared with inactive CD and control
Abbreviations: BMI, body mass index; CD, Crohn disease; CDAI, Crohn’s Disease Activity Index; CRP, C ‑reactive 
protein; IQR, interquartile range; NA, not applicable
tAbLE 2 Differences in the levels of selected biomarkers between patients with active and inactive Crohn disease 
and control group
Parameter Active CD Inactive CD Control
MDA, nmol/g of protein Serum 7.8 (2.0–15.7)a 4.1 (3.5–5.8) 2.6 (1.6–4.2)
Saliva 9.6 (2.7–26.8)a,b 6.3 (4.9–32.7)b 4.5 (2.7–6.8)b
FRAP, mmol/g of protein  Serum 0.01 (0.01–0.02)a 0.02 (0.01–0.03) 0.02 (0.02–0.03)
 Saliva 0.04 (0.02–0.07) 0.03 (0.02–0.04) 0.05 (0.04–0.06)
GSH, μmol/g of protein  Serum 6.1 (3.4–8.9)a 8.7 (4.6–16.9) 10.1 (8.3–13.6)
 Saliva 6.8 (2.1–14.3)a 9.25 (3.5–10.1) 12.6 (9.3–16.8)
CAT, IU/mg protein 8.6 (5.5–14.4)c 14.6 (6.0–18.3) 13.7 (6.9–17.5)
Data are presented as median (IQR).
a P <0.01 compared with inactive CD and control;   b P = 0.01 compared with serum MDA;  
c P = 0.001 compared with inactive CD and control; Kruskal–Wallis test with post hoc analysis
Abbreviations: CAT, catalase; FRAP, ferric reducing ability of plasma; GSH, glutathione; MDA, malondialdehyde; others, 
see tAbLE 1
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levels. Negative correlations were detected between 
GSH levels in serum and saliva and CRP levels and 
platelet count. Data are presented in tAbLE 3.
Correlations between CRP levels and CAT activ‑
ity, and MDA and FRAP levels in serum and saliva 
of CD patients are shown in tAbLE 4. MDA levels in 
serum and saliva positively correlated with CRP 
levels and negatively—with CAT activity. FRAP 
concentrations in serum and saliva negatively cor‑
related with CRP levels. Serum FRAP levels posi‑
tively correlated with CAT. GSH in serum and sa‑
liva negatively correlated with CRP levels; a pos‑
itive correlation was observed between GSH in 
serum and saliva and CAT activity.
The results of the ROC curve analysis compar‑
ing CRP and MDA levels in serum are presented 
in FIGurE 3. The analysis showed diagnostic utility 
of CRP and MDA in differentiating active from 
inactive CD (according to CDAI). The AUC for 
and saliva of CD patients and CDAI are presented 
in FIGurEs 1 and 2. There were strong positive cor‑
relations between MDA concentrations in serum 
and saliva and CDAI values. Negative correlations 
were observed between serum FRAP levels and 
and CDAI values. Negative correlations were also 
detected between serum GSH levels and saliva 
and CDAI values. There were significant positive 
correlations between MDA levels in serum and 
saliva of CD patients and CRP levels and platelet 
count, as well as negative correlations between 
serum and saliva MDA levels and body mass in‑
dex and hemoglobin levels.
Positive correlations were detected between 
FRAP levels in serum and hemoglobin levels. Neg‑
ative correlations were found between FRAP lev‑
els in serum and saliva and CRP levels and platelet 
count. Positive correlations were observed between 
GSH level in serum and BMI and hemoglobin 
tAbLE 3 Coefficients of correlation between the selected serum and saliva biomarkers and body mass index, Crohn’s Disease Activity Index, 
C ‑reactive protein and hemoglobin levels, and platelet and white blood cell count in patients with active Crohn disease.
Biomarker BMI CDAI CRP Hemoglobin Platelets White blood cells
FRAP Serum r = 0.3,
P = 0.06
r = –0.8
P <0.001
r = –0.5
P <0.001
r = 0.6
P <0.001
r = –0.5
P <0.001
r = –0.1
P = 0.40
Saliva r = 0.3
P = 0.13
r = –0.4
P = 0.04
r = –0.4
P = 0.01
r = 0.2
P = 0.19
r = –0.5
P = 0.01
r = –0.3
P = 0.07
MDA Serum r = –0.40
P = 0.01
r = 0.8
P <0.001
r = 0.6
P <0.001
r = –0.6
P <0.001
r = 0.6
P <0.001
r = 0.2
P = 0.23
Saliva r = –0.4
P = 0.02
r = 0.8
P <0.001
r = 0.7
P <0.001
r = –0.5
P = 0.01
r = 0.6
P = 0.001
r = 0.4
P = 0.05
GSH Serum r = 0.3
P = 0.04
r = –0.8
P <0.001
r = –0.5
P <0.001
r = 0.5
P <0.001
r = –0.6
P <0.001
r = –0.2
P = 0.19
Saliva r = 0.1
P = 0.68
r = –0.5
P = 0.01
r = –0.6
P <0.001
r = 0.3
P = 0.11
r = –0.5
P = 0.01
r = –0.3
P = 0.19
Abbreviations: see tAbLEs 1 and 2
FIGurE 1 Spearman 
correlation of 
malondialdehyde (MDA) 
levels in the serum of 
patients with Crohn 
disease and the disease 
activity according to 
the Crohn’s Disease 
Activity Index (CDAI)
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diagnosis of CD patients. This is the first report 
of the differences in indices of lipid peroxidation 
and antioxidant levels in serum and saliva of pa‑
tients with active and inactive CD. Comparing 
the results of other studies, we noted an upward 
trend for MDA levels, depending on the severi‑
ty of CD. In addition, the increased MDA levels 
correlate with visible symptoms of inflammation 
and can be a good indicator for early diagnosis. 
Additionally, this parameter correlated positive‑
ly with CDAI and CRP, and negatively with FRAP, 
GSH, and CAT.
Oxidative stress is involved in the  patho‑
genesis of numerous diseases and is associated 
with an increase in lipid peroxidation, as indi‑
cated by higher concentrations of its products, 
such as MDA.11,16,18,21,44,45 These compounds 
participate in apoptosis signaling by influenc‑
ing the link between Bcl ‑2 and Bax, and in mito‑
chondrial regulation and the regulation by CD8+ 
lymphocytes through nuclear factor ‑κB (NF ‑κB) 
activity.5,6,14,20,46
The major intracellular antioxidant enzymes 
are superoxide dismutase (SOD), GSH, and 
CAT.12,15,47 The biological roles of GSH include 
protecting against oxidative stress, in addition 
to many other activities.6,48,49 A shortage of GSH 
or disturbance in its homeostasis contributes to 
the pathogenesis of several diseases. CD is asso‑
ciated with decreased intestinal mucosal levels of 
GSH and SOD, which supports the role for oxida‑
tive stress in CD.3,21 Activities of low ‑molecular‑‑
weight antioxidants, proteins, and enzymatic sys‑
tems contribute to the total plasma antioxidant 
capacity.3,13,43,47,48 CD patients have low levels of 
numerous antioxidants (eg, vitamins A, C, and 
E, SOD, GSH, and CAT) in blood and the intesti‑
nal mucosa.13,15,21,25,42,43
The effects of oxidative stress on CD are in‑
tensified by lipid peroxidation.3,18,45 The role of 
MDA in CD remains unclear. MDA participates 
CRP was 0.85 (95% CI, 0.76–0.94) with a cut‑
‑off point of >4.25, Youden index of 0.62, sensi‑
tivity of 0.62, and specificity of 1.00. For MDA, 
the AUC was 0.95 (95% CI, 0.90–1.00), the cut‑
‑off point was >3.82, sensitivity was 0.93, and 
specificity was 0.87. The  AUC for FRAP was 
0.94 (95% CI, 0.89–0.99) and for GSH, 0.86 (95% 
CI, 0.78–0.95).
dIscussIon CD is a  chronic inflammatory 
condition involving a disrupted oxidant–anti‑
oxidant balance that leads to the development 
of complications.3,11,15,21,25,42 CD is associated 
with increased oxidative stress, which is accom‑
panied by increased production of ROS; howev‑
er, the data on the levels of antioxidants in CD 
are inconclusive.10,43
In this study, we examined the disease activ‑
ity in relation to inflammation and oxidant–an‑
tioxidant indicators as a potential tool in early 
FIGurE 2 Spearman 
correlation of 
malondialdehyde (MDA) 
levels in the saliva of 
patients with Crohn 
disease and the activity of 
the disease according to 
the Crohn’s Disease 
Activity Index (CDAI)
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tAbLE 4 Coefficients of correlation between the analyzed serum and saliva biomarkers 
and C ‑reactive protein level and catalase activity in patients with Crohn disease
Parameter CRP CAT
MDA Serum r = 0.6
P <0.001
r = –0.6
P <0.001
Saliva r = 0.7
P <0.001
r = –0.4
P = 0.001
FRAP Serum r = –0.5
P <0.001
r = 0.5
P <0.001
Saliva r = –0.4
P = 0.01
r = 0.3
P = 0.11
GSH Serum r = –0.5 r = 0.8
P <0.001 P = 0.001
Serum r = –0.6
P <0.001
r = 0.4
P = 0.003
Abbreviations: see tAbLEs 1 and 2
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precursor of hydroxyl radicals, ROS, particu‑
larly efficient in initiation of lipid peroxidation 
if it is insufficiently neutralized, which is indi‑
cated by decreased activity of CAT determined 
in our study in white blood cells. As we demon‑
strated in our previous study, red blood cells, 
and in this study, white blood cells—as the key 
cells providing antioxidant defense mechanisms 
(eg, antioxidant enzymes)—are threatened in 
patients with CD due to, for example, enzyme 
damage or exhaustion of their processing ca‑
pacity in relation to the elevated amount of the 
substrate. This leads to persistent imbalance and 
development of oxidative stress. Then, elimina‑
tion of hydrogen peroxide may be inhibited. In 
this study, the activity of CAT, an enzyme par‑
ticipating in neutralization of hydrogen perox‑
ide was reduced, while the activity of SOD was 
significantly reduced in active disease, as re‑
ported in our earlier study.29 This may result in 
the formation of lipid hydroperoxides, which 
not only disturb the integrity of cell membranes, 
but also may exacerbate the existing inflamma‑
tion through attracting neutrophils and stimu‑
lation of proinflammatory cytokines.10,53 Thus, 
we believe that, in this case, oxidative stress in‑
dices in combination with the indices of antiox‑
idant defense better reflect the degree of the ac‑
tual changes in the diagnosis of CD than CRP 
alone. This applies particularly to changes which 
may not be visible, especially in inactive disease.
In this study, antioxidant activity, measured 
using FRAP and GSH levels, was significantly re‑
duced in CD. FRAP levels were lower in the se‑
rum of active CD patients than inactive CD pa‑
tients and controls, which suggests antioxidant 
in apoptosis signaling and in p85 ‑dependent 
regulation through NF ‑κB/p65.14,15,46 Oxidative 
stress suppresses signal transfer and transduc‑
tion mechanisms, which results in enterocyte 
dysfunction and apoptosis, and functional im‑
pairment.12,14,15,17,18 A better understanding of 
the role of oxidative stress in CD may facilitate 
the development of antioxidant therapies.15,49
Kruidenier et al50 confirmed that oxidative 
stress may occur in CD when there is an imbal‑
ance in the levels of ROS and antioxidants. Ja‑
hanshahi et al51 showed that TBARS levels were 
significantly increased and antioxidant activi‑
ty was lower in the saliva of CD patients than 
in controls. These results were in line with a re‑
port by Alzoghaibi et al52 that plasma MDA lev‑
els were higher in CD patients than in controls. 
Boehm et al10 evaluated the diagnostic utility of 
MDA/TBARS as markers of CD and concluded 
that the combination of CRP and MDA/TBARS 
may facilitate the diagnosis of CD.
Our analysis of the ROC curves revealed the di‑
agnostic utility of CRP and MDA in differentiat‑
ing patients with active and nonactive CD. CRP 
currently constitutes the best biochemical marker 
of CD; however, it is far more useful in the mon‑
itoring of the course of the disease than for its 
diagnosis. Cases are known where an endoscopic 
examination revealed inflammation but CRP lev‑
els were within the reference range.34
It was reported that hydrogen peroxide it‑
self acts as an immunomodulator capable of at‑
tracting neutrophils, intensifying white blood 
cell rolling, lymphocyte ‑T activation, and angio‑
genesis,34,53 thus worsening the ongoing inflam‑
mation. Moreover, hydrogen peroxide is a key 
FIGurE 3 Receiver 
operating characteristic 
curve analysis comparing 
serum C ‑reactive  
protein (CRP) and 
malondialdehyde (MDA) 
levels. Diagonal segments 
are produced by ties.
1-specificity
MDA
CRP
Reference line
0.0
0.2
0.4
0.6
0.8
1.0
Se
ns
iti
vi
ty
0.0 0.2 0.4 0.6 0.8 1.0
orIGInAL ArtIcLE Lipid peroxidation and Crohn disease 369
the statistical power of the tests and thus the val‑
ue of the research.
conclusions The increased lipid peroxidation 
product (MDA) and decreased FRAP and GSH 
levels in the serum and saliva of patients with 
active CD, and to a lesser extent those with inac‑
tive CD, confirm that CD patients are under ox‑
idative stress. Positive correlation of MDA with 
the clinical activity and inflammation, and com‑
parison of the ROC curves for MDA and CRP sug‑
gest that MDA could be a valuable indicator in 
early diagnosis of CD.
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